Tetrahydrozoline

Summary

Tetrahydrozoline (CHEMBL1266) is an approved small-molecule sympathomimetic agent (ATC S01GA52); indicated across 3 conditions including eye allergy and dry eye syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01GA52 (+3 more)
• Indications: 3 conditions
• Clinical trials: 3
• Chemistry: 200.28 Da · C13H16N2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1266
Name	Tetrahydrozoline
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5419
ChEBI	CHEBI:28674
ATC	S01GA52, R01AA06, R01AB03, S01GA02
Molecular formula	C13H16N2
Molecular weight	200.28
InChIKey	BYJAVTDNIXVSPW-UHFFFAOYSA-N

SMILES: C1CC(C2=CC=CC=C2C1)C3=NCCN3

IUPAC name: 2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole

Pharmacological roles (ChEBI): sympathomimetic agent, nasal decongestant.

Also known as: Caltheon, Tetrahydrozoline, Tetrizolina, Tetryzoline, SID90341828, soothe, TETRAHYDROZOLINE, tetrahydrozoline, TETRAHYDROZOLINE HYDROCHLORIDE, TETRYZOLINE, tetryzoline

Parent form; salt/anhydrous children: CHEMBL1200413

Patent coverage: 1,559 distinct patent families (5,584 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5,554 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Alpha-2A adrenergic receptor, Adrenergic receptor alpha-1, Adrenergic receptor alpha-2, Adrenergic receptor alpha, 5-hydroxytryptamine receptor 1A, Alpha-1A adrenergic receptor, Mu-type opioid receptor.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRA1A	8.21	AC50	6.1	nM	CHEMBL_ACT_25208796
P15823	7.96	Ki	11	nM	CHEMBL_ACT_14624393
P19328	7.52	IC50	30	nM	CHEMBL_ACT_170357
ADRA2A	7.18	AC50	66.7	nM	CHEMBL_ACT_25156728
P15823	5.8	IC50	1600	nM	CHEMBL_ACT_170356
HTR1A	5.72	AC50	1905	nM	CHEMBL_ACT_25165323

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
eye allergy	4	MONDO:0005551	EFO:0005751
dry eye syndrome	0	MONDO:0006733	EFO:1000906

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
Not specified	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00284999	PHASE4	COMPLETED	Soothe Versus Refresh
NCT01013077	Not specified	COMPLETED	The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability
NCT03505203	Not specified	COMPLETED	Sleep-Safe: A Strong African American Families Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).